Literature DB >> 3421570

Lovastatin, nicotinic acid, and rhabdomyolysis.

P Reaven, J L Witztum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3421570     DOI： 10.7326/0003-4819-109-7-597_2

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  19 in total

Review 1.  Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.

Authors:  M H Davidson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Myopathic effects of lovastatin.

Authors:  W N Suki
Journal:  West J Med       Date:  1991-02

3.  A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

Authors:  Donald B Hunninghake; Mark E McGovern; Michael Koren; Ronald Brazg; David Murdock; Stuart Weiss; Thomas Pearson
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

Review 4.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

6.  [Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline].

Authors:  M Dallaire; M Chamberland
Journal:  CMAJ       Date:  1994-06-15       Impact factor: 8.262

7.  Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  Chantale Simard; Paul Poirier
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 8.  Clinical pharmacokinetics and practical applications of simvastatin.

Authors:  V F Mauro
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

9.  Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.

Authors:  Barbara J Meyer; Tone Hammervold; Arild Chr Rustan; Peter R C Howe
Journal:  Lipids       Date:  2007-02-08       Impact factor: 1.880

Review 10.  Combination lipid-lowering therapy in diabetes.

Authors:  Michael H Davidson
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.